Proserin-Darnitsa

Selected form

Neostigmine Methylsulfate

Method of action: Anticholinesterase, Increased Smooth Muscle Contractility, Uterotonizing

Treatment option: Glaucoma, Meningitis, Neuritis, Polio, Weakness, Crush Injury, Encephalitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Proserin-Darnitsa

Quick Facts: Proserin-Darnitsa

Property	Description
Active ingredient	Neostigmine Methylsulfate
Form	Injectable solution
Pharmacological class	Acetylcholinesterase Inhibitor
General purpose	Cholinergic muscle stimulant
Origin	Synthetic

What Type of Medicine is Proserin-Darnitsa?

Proserin-Darnitsa is a prescription-only, synthetic, single-component pharmaceutical product from the manufacturer Darnitsa. Its sole active ingredient is Neostigmine Methylsulfate (INN). The drug is formally classified as a reversible Acetylcholinesterase Inhibitor and a Parasympathomimetic Agent. This classification defines its established function as a Cholinergic Muscle Stimulant.

The unique quaternary ammonium structure of Neostigmine Methylsulfate is a differentiating chemical feature that prevents the substance from crossing the blood-brain barrier. This property localizes the drug’s primary action to the peripheral nervous system, focusing its therapeutic effect on the nerve-muscle connections. This indicates that the medicine’s main influence is directed toward the body's muscle function, rather than the central nervous system.

Composition and Form: The Injectable Solution

This medicine is supplied exclusively as a sterile injectable solution in an aqueous vehicle, representing a parenteral form of administration (such as intravenous, intramuscular, or subcutaneous injection). The injectable route is essential because the active ingredient's chemical makeup leads to inadequate absorption if administered orally, requiring direct entry into the circulation.

General Purpose as a Cholinergic Muscle Stimulant

The essential general purpose of Proserin-Darnitsa is to promote enhanced cholinergic transmission. By allowing the neurotransmitter acetylcholine to accumulate at the nerve-muscle connection points, the drug amplifies the signal sent to the skeletal muscle fibers. The benefit derived from this action is the restoration or increase of function, tone, and contraction strength in muscles where the natural nerve signal has been weakened. The compound Neostigmine is recognized for its essential role in these situations and is included on the Model List of Essential Medicines.

Regulatory References

What side effects are possible with Proserin-Darnitsa?

Possible Side Effects and Safety Information

The safety profile of this medicine is characterized by adverse reactions that predominantly result from its action as a cholinergic stimulant, affecting the peripheral nervous system. Regulatory documents classify the associated safety events by frequency and the body system affected.

Adverse Reaction Scope	Official Regulatory Content
Key adverse reaction categories	Effects arise mainly from peripheral cholinergic overstimulation, involving smooth muscle and exocrine glands.
System-organ classes involved	Gastrointestinal disorders (e.g., nausea, vomiting, diarrhea), Cardiac disorders (bradycardia, arrhythmias), Musculoskeletal disorders (cramps, fasciculations), and increased secretions.
Commonly Documented Reactions	Nausea, vomiting, diarrhea, abdominal cramps, increased salivation, muscle fasciculations (twitching), and bradycardia (slowed heart rate) are frequently listed.
Serious Adverse Reactions	Officially documented serious events include Cardiac Arrest, Severe Bradycardia, Circulatory Collapse, and Severe Bronchospasm. The frequency of these severe reactions is often classified as Not Known in regulatory summaries.

Safety Restrictions and Specific Considerations

The official labeling outlines mandatory safety constraints. The medicine is contraindicated (must not be used) in patients with a known hypersensitivity to the drug or in the presence of mechanical obstruction of the intestinal or urinary tracts, or peritonitis.

Regulatory documents also advise caution for specific patient populations, including individuals with bronchial asthma, cardiac arrhythmias, or peptic ulcer disease. Furthermore, severe cholinergic adverse effects are noted to be more pronounced following rapid intravenous administration, a time-related safety pattern defined in official documents.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Neostigmine Methylsulfate is officially classified as a Cholinergic Crisis, which is a life-threatening medical emergency requiring immediate professional intervention. This acute state results from an over-exaggeration of the drug’s intended effects.

Documented Manifestations and Severe Outcomes

Regulatory labels document severe manifestations including marked muscle weakness and fasciculations, which may progress to respiratory paralysis. Cardiac effects include bradycardia, hypotension, and the documented risk of cardiac arrest. Other signs are excessive salivation, increased bronchial secretions, miosis, and gastrointestinal distress (nausea, vomiting, abdominal cramps).

Mandated Emergency Actions

Any suspected overdosage requires the drug to be discontinued immediately. Immediate medical help must be sought for any signs of crisis. Atropine Sulfate (intravenous) is the documented antidote for counteracting the severe muscarinic effects. Treatment requires intensive hospital observation, which includes continuous ECG monitoring and often necessitates assisted mechanical ventilation to maintain adequate respiration. In Myasthenia Gravis patients, the crisis must be accurately differentiated from a Myasthenic Crisis, as regulatory guidance notes the treatments are opposing.

Therapeutic Uses of Proserin-Darnitsa

What Proserin-Darnitsa treats: main uses and benefits

Proserin-Darnitsa is a medication belonging to the pharmacological group of anticholinesterase agents. It works by inhibiting the enzyme acetylcholinesterase, which leads to an accumulation of acetylcholine at nerve endings. This process enhances the transmission of nerve impulses to muscles and organs.

Main Therapeutic Uses

The medication is primarily utilized in neurology and surgery to address conditions involving impaired nerve-to-muscle communication and reduced muscle tone. Its main applications include:

Myasthenia Gravis: A chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles. The medication helps improve muscle strength by prolonging the action of acetylcholine at the neuromuscular junction.
Recovery from Paralysis: It is used during the recovery phase following meningitis, poliomyelitis, or encephalitis, where it aids in restoring motor function.
Neuritis and Nerve Atrophy: It may be applied in cases of peripheral nerve inflammation or optic nerve atrophy to support nerve conduction.
Postoperative Care: In surgical settings, it is used to treat or prevent intestinal atony (lack of muscle tone in the intestines) and urinary bladder atony, helping to restore normal organ function after anesthesia.
Neuromuscular Blockade Reversal: It serves as an antidote to non-depolarizing muscle relaxants used during general anesthesia, helping to restore spontaneous breathing and muscle movement.

Benefits of Treatment

The therapeutic benefits of Proserin-Darnitsa center on its ability to restore physiological movement and internal organ rhythmicity. By facilitating impulse transmission, the medication assists in:

Increasing the tone of skeletal muscles and improving motor coordination.
Stimulating the gastrointestinal tract's motility, which prevents complications such as postoperative ileus.
Enhancing the contractility of the bladder to resolve urinary retention.
Improving secretory functions of the bronchial, sweat, and digestive glands.

Regulatory References

Therapeutic Goods Administration (TGA) on Neostigmine

Eligibility and Restrictions for Use

Who can and cannot use Proserin-Darnitsa?

This section details the official patient eligibility criteria for Proserin-Darnitsa (Neostigmine Methylsulfate) as defined by government regulatory documents.

Populations Excluded (Contraindications)

The medicine is contraindicated (must not be used) in patients with the following conditions:

Known Hypersensitivity (allergy) to neostigmine methylsulfate.
Mechanical Obstruction of the intestinal tract or the urinary tract.
Peritonitis (inflammation of the abdominal lining).

Conditional Use and Limitations

Age Group / Condition	Official Regulatory Status
Pediatric Patients (< 2 years)	Not recommended for use in children under 2 years of age.
Older Adults (Geriatric)	May be more susceptible to dysrhythmias (irregular heart rhythms), requiring caution.
Pregnancy	Use only if clearly needed; warnings exist regarding potential uterine irritability and premature labor when administered near term.
Lactation	Caution must be exercised, as it is not known if the active ingredient is excreted in human milk.
Cardiovascular Disease	Caution is required in patients with coronary artery disease, cardiac arrhythmias, or recent acute coronary syndrome.
Other Conditions	Caution is also required in patients with bronchial asthma, epilepsy, hyperthyroidism, Parkinsonism, or peptic ulceration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Neostigmine Methylsulfate defines interaction patterns primarily through pharmacodynamic effects on the nervous and muscular systems.

Pharmacodynamic Interactions and Restrictions

Interaction Entity	Official Regulatory Statement
Anticholinergic Agents (e.g., Atropine Sulfate, Glycopyrrolate)	Co-administration is mandatory prior to or concomitantly with Neostigmine to lessen the risk of bradycardia and mitigate muscarinic effects.
Non-depolarizing Muscle Relaxants	Used for pharmacodynamic antagonism to officially reverse the effects of these agents (e.g., rocuronium, vecuronium).
Depolarizing Muscle Relaxants (e.g., Succinylcholine)	Co-administration is restricted as Neostigmine does not antagonize the effect and may prolong the Phase I block.
Other Cholinesterase Inhibitors / Beta-Blockers	Co-administration may result in additive effects, increasing the risk or severity of cholinergic signs and symptoms, particularly bradycardia.

Population-Specific Notes

Regulatory documents note that patients with pre-existing conditions, specifically coronary artery disease or cardiac arrhythmias, may be particularly sensitive to the hemodynamic effects (e.g., hypotension) resulting from Neostigmine administration. No specific interactions with food, alcohol, or herbal products are explicitly documented in primary regulatory labeling.

Mechanism of Action

Proserin-Darnitsa (neostigmine) is a chemical substance that influences the transmission of nerve signals through targeted enzyme inhibition. Its core mechanism involves acting as a reversible inhibitor of the enzyme acetylcholinesterase (AChE). By blocking AChE, the compound prevents the rapid breakdown of the key chemical messenger, acetylcholine (ACh), causing its concentration to accumulate and remain active longer in the synaptic cleft. This potentiation of cholinergic signaling is confined to the peripheral nervous system because the compound does not readily cross the blood-brain barrier. The augmented ACh levels lead to sustained stimulation of receptors on skeletal muscles, resulting in increased magnitude and duration of muscle contraction. Concurrently, this action enhances activity in the autonomic nervous system, specifically increasing the contractility of involuntary smooth muscles found in the gastrointestinal tract and the urinary bladder. This modulation results in a heightened state of motility and evacuation functions.

Dosage and Administration Information

How to Use Proserin-Darnitsa (Neostigmine Methylsulfate Injection)

Proserin-Darnitsa contains the active substance Neostigmine Methylsulfate and is administered as an injection exclusively in a hospital or clinical setting by a trained healthcare provider. Its primary use is to reverse the effects of certain non-depolarizing neuromuscular blocking agents following surgery.

Official Administration Guidelines

Administration Scope	Administration Guidelines
Route of Administration	Intravenous (IV) bolus injection. The injection is administered slowly, typically over a period of at least 60 seconds.
Official Dosing	The recommended weight-based dose range for adults is 0.03 mg/kg to 0.07 mg/kg, not to exceed a 5 mg total maximum dose.
Dose Specificity	A lower dose (0.03 mg/kg) is used for reversal of shorter-acting agents or when recovery is substantial (e.g., first twitch response > 10% of baseline). A higher dose (0.07 mg/kg) is recommended for longer-acting agents or when rapid recovery is needed.
Preparation	The solution for injection is provided ready-to-use in a pre-filled syringe (e.g., 3 mg per 3 mL).
Special Condition	An anticholinergic agent (such as atropine or glycopyrrolate) must be administered prior to or concomitantly with Neostigmine Methylsulfate Injection using separate syringes.
Monitoring	The use of a peripheral nerve stimulator is recommended to determine the timing and dosage for administration and to monitor the patient's recovery from neuromuscular blockade.
Age-Specific Use	Adult dosing guidelines should be followed when administering the injection to pediatric patients, including neonates.

The healthcare provider must ensure the patient is well-ventilated and a patent airway is maintained before and until complete recovery of normal ventilation has occurred. Satisfactory recovery should be confirmed by adequate skeletal muscle tone and respiratory measurements.

Recent Clinical Evidence

Research evidence / Overview of studies for Proserin-Darnitsa

Evidence for Acute Use in Surgical Recovery

This section will summarize the extensive research, including meta-analyses of randomized controlled trials (RCTs), that has examined the medicine's role in the context of muscle function recovery after general anesthesia. It will describe the objective measures and time-critical functional outcomes that these studies track.

The research for Proserin-Darnitsa primarily consists of large, short-term RCTs that studied its use in the context of supporting muscle function after the use of relaxants. These studies monitored objective functional outcomes, such as the time required for muscle function to return to a threshold of safety, and time needed before the removal of the patient's breathing tube (extubation). This research was conducted on adult patients, with specific trials also observing responses in pediatric populations.

Findings reported measurements that were associated with a shorter time to the achievement of objective functional recovery milestones in the observed populations, compared to when no reversal agent was applied. However, research comparing this medicine with newer alternatives often described patterns where the measured time to recovery goals was longer. Furthermore, research has consistently reported that the objective functional threshold was not reliably achieved in studies when profound or deep muscle relaxation was present.

Evidence for Symptom Management in Neuromuscular Conditions

This block will outline the nature of the research available for managing chronic weakness associated with conditions like Myasthenia Gravis. It will describe the evidence, which includes historical observational studies and small intervention trials, and the symptomatic outcomes these studies track.

This medicine, and others of its class, was evaluated in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as Myasthenia Gravis (MG). The evidence base here consists primarily of historical observational cohorts and small intervention studies. Studies monitored outcomes related to daily functioning and activity level, including measures of weakness in the limbs and eyes.

Findings from small studies and clinical reviews reported measurements of changes in specific muscular symptoms following the administration of this medicine. This evidence contributes to understanding symptom patterns in this condition, but the reported patterns of change were observed only in the specific, small populations studied.

What Is Still Uncertain About Proserin-Darnitsa

This final section will synthesize the main evidence gaps, including areas of inconsistent research findings, limitations in study depth or sample size, and functional boundaries that require further investigation.

Despite the large amount of research, some aspects of the evidence landscape remain uncertain. For the surgical recovery use, research indicates that the functional threshold for achieving full recovery may not be met when muscle relaxation is very deep. For the smooth muscle functions, evidence quality varies across studies, with some meta-analyses reporting high data inconsistency (heterogeneity), which can make findings difficult to generalize. Data for certain groups remain insufficient, meaning more research is needed to fully understand the medicine’s use in all populations and across all levels of symptom intensity.

Key Studies & References

Safety and Efficacy of Neostigmine Methylsulfate for Treating Acute Colonic Pseudo-Obstruction (ACPO)

Frequently Asked Questions (FAQ)

Common questions about Proserin-Darnitsa (FAQ)

Q: Is Proserin-Darnitsa safe to use while breastfeeding?

Official product information states that it is not known if the active ingredient, neostigmine, passes into human milk. Regulatory labeling indicates that caution should be used if the drug is administered to a nursing parent. Monitoring of the newborn for potential effects is generally recommended.

Q: What is the minimum recommended adult dose for reversing neuromuscular blockade?

Regulatory documents define the dose for reversing the effects of certain muscle relaxants as a weight-based range. The lower dose range is often indicated for use when a patient's muscle recovery is already substantial. Dosing is determined by the healthcare provider based on factors such as patient weight and objective monitoring of muscle function.

Q: Why is Proserin-Darnitsa administered with an anticholinergic agent like atropine?

Proserin-Darnitsa is a cholinergic stimulant, which enhances signaling in the nervous system. To counteract the unwanted effects of this stimulation on involuntary systems, such as a drop in heart rate (bradycardia), an anticholinergic agent must be given beforehand or at the same time. This mandatory co-administration is intended to lessen the risk of these specific peripheral effects.

Q: What specific conditions, if present in a patient, would prevent a doctor from administering this drug?

The official product labeling lists several conditions where the drug is contraindicated, meaning it must not be used. These conditions include a known allergy to neostigmine, peritonitis (inflammation of the abdominal lining), and and any mechanical obstruction in the intestinal or urinary tracts.

Q: Does Proserin-Darnitsa have any specific effects on the eye, such as pupillary changes?

Adverse effects related to eye function have been reported in official documents. These reactions include miosis (constriction of the pupil) and ciliary muscle spasm, which may lead to blurred vision. These effects are linked to the drug's action on the peripheral nervous system.

Q: How quickly does Neostigmine Methylsulfate begin to work after being injected? (Onset of action)

Clinical studies summarized in regulatory documents indicate a time frame for muscle function recovery. After administration, recovery of muscle function is generally achieved within 10 to 20 minutes for the reversal of neuromuscular blockade. This process is closely monitored by the healthcare team.

Q: How does the injection process for pediatric patients differ from adult administration?

Official information specifies that the same weight-based dosing guidelines used for adults should be followed for pediatric patients. An anticholinergic agent is administered before the Neostigmine in children as a measure to reduce the probability of developing a slow heart rate (bradycardia) and low blood pressure (hypotension).

How should Proserin-Darnitsa be stored and disposed of?

How to Store and Dispose of Proserin-Darnitsa

Official regulatory documents define specific requirements for the storage and disposal of Proserin-Darnitsa (Neostigmine Methylsulfate injection).

Storage and Handling

The medicine must be stored at Controlled Room Temperature, typically defined as 20^circmathrmC to 25^circmathrmC, and protected from light. It is essential to keep the injection in its original container to maintain this light protection. The product must be stored out of the sight and reach of children.

Solution Integrity and Stability

The stability of the injection is not guaranteed once it has been diluted. If only a portion of the solution is used from a single-dose container, the remaining solution must be discarded.

Disposal Requirements

Any unused or expired medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Russia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z